Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 840 results for "nexium"

US court refuses Ranbaxy plea to block ANDA nod for 2 drugs
Money Control

RANBAXY LABORATORIES : D.C. Federal Court Refuses Ranbaxy's Ap...

Ranbaxy Laboratories Ltd had filed a complaint against the FDA in D.C. Federal Court and had also asked the court for a temporary restraining order to prevent any further action by FDA until Ranbaxy's case is decided. (c) 2014 GlobalData ... 4 Traders, 3 weeks ago
[x]  

68 images for nexium

NDTV Profit, 2 weeks ago
Money Today, 2 weeks ago
WilmerHale, 1 week ago
Pharma Letter, 1 week ago
FDA News, 1 week ago
BusinessWeek, 2 weeks ago
BusinessWeek, 2 weeks ago
Money Control, 2 weeks ago
Yahoo! News Australia, 2 weeks ago
Livemint.com, 2 weeks ago
FDA News

Jury Sides With AstraZeneca and Ranbaxy in Nexium Pay-for-Delay Case

A jury found that AstraZeneca and Ranbaxy didn't conspire to delay launching a generic version of the heartburn drug Nexium. Plaintiffs in the multi-district case, consolidated in Massachusetts district court, alleged that AstraZeneca paid ...
 FDA News1 week ago AstraZeneca's Move to Protect Nexium Market Ruled Legal  MedPage Today1 week ago AZ triumphs in Nexium pay-for-delay trial  Pharmafocus1 week ago AstraZeneca scores a victory in pay-for-delay Nexium case  FiercePharma1 week ago
[x]  
WKRB News

Ranbaxy and AstraZeneca Win Antitrust Trial on Nexium

A jury in Massachusetts found that an agreement made between Ranbaxy and AstraZeneca to delay launch of a generic version of Nexium the heartburn drug of AstraZeneca was not anticompetitive. The verdict was handed down this past Friday in a ...
 WKRB News1 week ago AstraZeneca, Ranbaxy prevail in Nexium antitrust trial  CNBC2 weeks ago AstraZeneca : Ranbaxy prevail in Nexium antitrust trial  4 Traders2 weeks ago US court relief for Ranbaxy  The Telegraph2 weeks ago
[x]  
Financial Express

AstraZeneca, Ranbaxy Laboratories prevail, Nexium drug deal not anti-competitive

Summary In a landmark judgement for pharma sector, a US jury has ruled that AstraZeneca's patent litigation settlement for blockbuster drug Nexium… The lawsuit challenged a settlement between AstraZeneca and Ranbaxy Laboratories that allowed ...
 Financial Express2 weeks ago AstraZeneca-Ranbaxy drug settlement not anti-competitive  Business Standard2 weeks ago
Reuters

Astra says U.S. Nexium antitrust case returns favourable ruling

LONDON, Dec 5 (Reuters) - AstraZeneca said a jury in the U.S. ruled in its favour in an antitrust litigation over heartburn drug Nexium, a case brought against it by various buying groups who challenged a previous settlement. The company said it ...
 CNBC2 weeks ago
[x]  

AstraZeneca Dodges $10 Billion Trial Threat Over Nexium Deal

(Updates with juror's comment in ninth paragraph.) Dec. 5 (Bloomberg) -- In a landmark U.S. trial, AstraZeneca Plc dodged what might have been a $10 billion damages award after a jury found its payment to Ranbaxy Laboratories Ltd. to delay a ...
 La Repubblica2 weeks ago
BusinessWeek

AstraZeneca Trial Over Generic Nexium Delay Heading to Jury

(Updates with company responses in ninth paragraph.) Dec. 3 (Bloomberg) -- AstraZeneca Plc will soon learn whether it faces billions of dollars in damages for paying a generic-drug maker to delay copies of its blockbuster heartburn tablet Nexium ...
 La Repubblica2 weeks ago AstraZeneca, American Eagle, GlobeRanger: Intellectual Property  Bloomberg2 weeks ago
[x]  
Livemint.com

AstraZeneca Fights Billions in Possible Damages in Nexium Trial

AstraZeneca Plc (AZN) , in a first trial since the U.S. Supreme Court ruled drugmakers can be sued over so-called pay-to-delay deals, is fighting to avoid what might be billions of dollars in damages over claims it illegally paid to block generic ...
 Bloomberg2 weeks ago

AstraZeneca could face hefty damages in Nexium case

News Editor AstraZeneca (NYSE:AZN) could be on the hook for substantial damages if it loses a trial in Boston involving Ranbaxy Laboratories Ltd. (OTC:RBXLY) (OTC:RBXZF) and their pay-to-delay agreement that blocked generic competition to Nexium.
 Seeking Alpha2 weeks ago
BusinessWeek

AstraZeneca Raises Forecast as Nexium Competitor Fails to Appear

Nov. 6 (Bloomberg) -- AstraZeneca Plc, the U.K. drugmaker that fought off a takeover attempt by Pfizer Inc., raised its forecasts for the second time this year after competition for one of its top-selling medicines failed to materialize as expected.
 Washington Post1 month ago AstraZeneca Raises Forecast on Lack of Nexium Competitor  Bloomberg1 month ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less